211 related articles for article (PubMed ID: 32349101)
1. ASSESSMENT OF HYPERREFLECTIVE FOCI AFTER BEVACIZUMAB OR DEXAMETHASONE TREATMENT ACCORDING TO DURATION OF MACULAR EDEMA IN PATIENTS WITH BRANCH RETINAL VEIN OCCLUSION.
Do JR; Park SJ; Shin JP; Park DH
Retina; 2021 Feb; 41(2):355-365. PubMed ID: 32349101
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion.
Moon SY; Cho KH; Woo SJ; Park SP; Kim YK
Korean J Ophthalmol; 2018 Feb; 32(1):29-37. PubMed ID: 29376223
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intravitreal bevacizumab for macular edema following branch retinal vein occlusion stratified by baseline visual acuity.
Kim M; Jeong S; Sagong M
Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):691-697. PubMed ID: 27796671
[TBL] [Abstract][Full Text] [Related]
5. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
6. Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion.
Kim M; Lee DH; Byeon SH; Koh HJ; Kim SS; Lee SC
Br J Ophthalmol; 2015 Sep; 99(9):1271-6. PubMed ID: 25777815
[TBL] [Abstract][Full Text] [Related]
7. Dexamethasone Intravitreal Implant Rescue Treatment for Bevacizumab Refractory Macular Edema Secondary to Branch Retinal Vein Occlusion.
Lee KH; Kang EC; Koh HJ
Korean J Ophthalmol; 2017 Apr; 31(2):108-114. PubMed ID: 28367038
[TBL] [Abstract][Full Text] [Related]
8. PERIPHERAL ISCHEMIC RETINAL PHOTOCOAGULATION IN ADDITION TO INTRAVITREAL BEVACIZUMAB VERSUS INTRAVITREAL BEVACIZUMAB ALONE FOR THE TREATMENT OF MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION: A Randomized Double-Masked Controlled Clinical Trial.
Nourinia R; Emamverdi M; Ramezani A; Amizadeh Y; Khorshidifar M; Behnaz N; Safi S
Retina; 2020 Jun; 40(6):1110-1117. PubMed ID: 31157710
[TBL] [Abstract][Full Text] [Related]
9. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
Tang F; Qin X; Lu J; Song P; Li M; Ma X
Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab versus Dexamethasone Implant in Macular Edema Secondary to Branch Retinal Vein Occlusion: Two-year Outcomes.
Ozkaya A; Tarakcioglu HN; Tanir I
Optom Vis Sci; 2018 Dec; 95(12):1149-1154. PubMed ID: 30451802
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of combined bevacizumab/targeted photocoagulation vs bevacizumab alone for macular oedema in ischaemic branch retinal vein occlusions.
Tomomatsu Y; Tomomatsu T; Takamura Y; Gozawa M; Arimura S; Takihara Y; Inatani M
Acta Ophthalmol; 2016 May; 94(3):e225-30. PubMed ID: 25989706
[TBL] [Abstract][Full Text] [Related]
12. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with Ozurdex®.
Coscas G; Coscas F; Zucchiatti I; Glacet-Bernard A; Soubrane G; Souïed E
Eur J Ophthalmol; 2011; 21(5):631-6. PubMed ID: 21500185
[TBL] [Abstract][Full Text] [Related]
13. Association Between Hyperreflective Dots on Spectral-Domain Optical Coherence Tomography in Macular Edema and Response to Treatment.
Hwang HS; Chae JB; Kim JY; Kim DY
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5958-5967. PubMed ID: 29183041
[TBL] [Abstract][Full Text] [Related]
14. Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion.
Tsagkataki M; Papathomas T; Lythgoe D; Kamal A
Semin Ophthalmol; 2015; 30(5-6):352-9. PubMed ID: 24875368
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage.
Zhao L; Li B; Feng K; Han L; Ma Z; Liu Y
Curr Eye Res; 2015 Jul; 40(7):752-6. PubMed ID: 25330134
[TBL] [Abstract][Full Text] [Related]
16. The Role of Serum Inflammation-Based Factors in Anti-Vascular Endothelial Growth Factor Treatment for Macular Edema Secondary to Retinal Vein Occlusion and Its Subtypes.
Rao J; Wu N; Qu X; Hu Y; Wu Y; Cheng Y; Yan L; Huang H; Li S; Shi L; Wu X
Ophthalmic Res; 2021; 64(2):237-245. PubMed ID: 32506058
[TBL] [Abstract][Full Text] [Related]
17. Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion.
Kang JW; Lee H; Chung H; Kim HC
Graefes Arch Clin Exp Ophthalmol; 2014 Sep; 252(9):1413-21. PubMed ID: 24577742
[TBL] [Abstract][Full Text] [Related]
18. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison.
Gado AS; Macky TA
Clin Exp Ophthalmol; 2014; 42(7):650-5. PubMed ID: 24612095
[TBL] [Abstract][Full Text] [Related]
19. The additive effect of intravitreal dexamethasone combined with bevacizumab in refractory diabetic macular edema.
Karimi S; Karrabi N; Hassanpour K; Amirabadi A; Daneshvar K; Nouri H; Abtahi SH
J Fr Ophtalmol; 2023 Nov; 46(9):1019-1029. PubMed ID: 37481454
[TBL] [Abstract][Full Text] [Related]
20. Comparing ranibizumab, dexamethasone implant, and combined therapy for macular edema secondary to branch retinal vein occlusion: a clinical trial.
Meng L; Yang M; Jiang X; Li Y; Han X
Int Ophthalmol; 2024 Jun; 44(1):262. PubMed ID: 38913192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
